CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids
Reyes Gonzalez-Exposito(Institute of Cancer Research), Marco Gerlinger(Royal Marsden NHS Foundation Trust)
Cited by 114
Related Papers
Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer
|bioRxiv (Cold Spring Harbor Laboratory)|2022|1